NEW YORK, NY, USA I June 28, 2013 I Kadmon Corporation, LLC, today announced the presentation of preclinical data demonstrating the natural resolution of inflammation with KD025, the Company‘s Phase 2, orally bioavailable, potent and highly selective inhibitor of ROCK 2 (Rho-associated coiled-coiled kinase 2). The data were presented by Alexandra Zanin-Zhorov, Ph.D., Kadmon‘s Senior Director of Immunology, at the 2013 meeting of the Federation of Clinical Immunology Societies (FOCIS) held June 27 – 30 in Boston, Massachusetts.
Recent literature points to the regulation of inflammation as being controlled by a balance between two of the immune system‘s unique CD4+ T lymphocyte subsets, T helper 17 cells (Th17), which favor inflammation, and regulatory T cells (Treg), which favor resolution. Disequilibrium in this balance, favoring inflammation, is thought to play a central role in the pathophysiology of autoimmune and other diseases, such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, psoriasis and lupus.
In the presented data, KD025 demonstrated the ability to naturally restore this equilibrium via selective inhibition of two key immune regulatory cytokines, IL-17 and IL-21, as well as inhibition of STAT3 phosphorylation and up-regulation of STAT5 phosphorylation. STAT3 and STAT5 are proteins known to regulate the development and survival of Th17 and Treg cells, respectively. The results were demonstrated in ex vivo human T cells, supporting their translation to the clinic.
“These results demonstrate the unique activity of KD025 in the immune system, not simply as an immunosuppressive agent, but as a drug capable of readjusting the balance of inflammatory and resolution signals in human immune responses,” said Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon. “We have not seen activity of this kind to date with any agent designed to modify these pathways, and its importance in a long list of diseases may be significant. We look forward to understanding how these results translate to the clinical setting and are moving ahead with a number of Phase 2 disease directed trials using KD025.”
About Kadmon Corporation
Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of hepatitis C, and is pioneering novel medicines in areas of serious disease, including oncology, infectious diseases, immunology and neurodegenerative diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal addressing some of today’s most pressing areas of unmet medical need. For more information, visit www.kadmon.com.
SOURCE: Kadmon
Post Views: 143
NEW YORK, NY, USA I June 28, 2013 I Kadmon Corporation, LLC, today announced the presentation of preclinical data demonstrating the natural resolution of inflammation with KD025, the Company‘s Phase 2, orally bioavailable, potent and highly selective inhibitor of ROCK 2 (Rho-associated coiled-coiled kinase 2). The data were presented by Alexandra Zanin-Zhorov, Ph.D., Kadmon‘s Senior Director of Immunology, at the 2013 meeting of the Federation of Clinical Immunology Societies (FOCIS) held June 27 – 30 in Boston, Massachusetts.
Recent literature points to the regulation of inflammation as being controlled by a balance between two of the immune system‘s unique CD4+ T lymphocyte subsets, T helper 17 cells (Th17), which favor inflammation, and regulatory T cells (Treg), which favor resolution. Disequilibrium in this balance, favoring inflammation, is thought to play a central role in the pathophysiology of autoimmune and other diseases, such as multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, psoriasis and lupus.
In the presented data, KD025 demonstrated the ability to naturally restore this equilibrium via selective inhibition of two key immune regulatory cytokines, IL-17 and IL-21, as well as inhibition of STAT3 phosphorylation and up-regulation of STAT5 phosphorylation. STAT3 and STAT5 are proteins known to regulate the development and survival of Th17 and Treg cells, respectively. The results were demonstrated in ex vivo human T cells, supporting their translation to the clinic.
“These results demonstrate the unique activity of KD025 in the immune system, not simply as an immunosuppressive agent, but as a drug capable of readjusting the balance of inflammatory and resolution signals in human immune responses,” said Samuel D. Waksal, Ph.D., Chairman and CEO of Kadmon. “We have not seen activity of this kind to date with any agent designed to modify these pathways, and its importance in a long list of diseases may be significant. We look forward to understanding how these results translate to the clinical setting and are moving ahead with a number of Phase 2 disease directed trials using KD025.”
About Kadmon Corporation
Kadmon Corporation, LLC, is a global company built on a 21st-century paradigm for the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of hepatitis C, and is pioneering novel medicines in areas of serious disease, including oncology, infectious diseases, immunology and neurodegenerative diseases. Emphasizing emerging concepts in molecular biology and genomics, Kadmon is developing treatments and treatment combinations that target the metabolomics and signaling pathways associated with disease, with the goal addressing some of today’s most pressing areas of unmet medical need. For more information, visit www.kadmon.com.
SOURCE: Kadmon
Post Views: 143
